Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Phase 2

Completed

Conditions: Cancer

First Posted Date: 2005-09-15

Last Posted Date: 2016-01-18

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 45

Registration Number: NCT00177242

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Phase 2

Completed

Conditions: Myelogenous Leukemia, Acute

Interventions: Drug: gefitinib

First Posted Date: 2005-08-16

Last Posted Date: 2014-05-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT00130702

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Gefitinib

First Posted Date: 2005-08-09

Last Posted Date: 2009-04-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 66

Registration Number: NCT00127829

Locations: 🇺🇸
Research Site, Palm Springs, California, United States

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Phase 2

Completed

Conditions: Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin

Interventions: Drug: Gefitinib
Radiation: Radiotherapy
Other: laboratory biomarker analysis
Procedure: Conventional surgery

First Posted Date: 2005-08-04

Last Posted Date: 2019-08-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00126555

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2012-07-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00103051

Locations: 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: gefitinib

First Posted Date: 2005-01-10

Last Posted Date: 2016-12-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 70

Registration Number: NCT00100945

Locations: 🇺🇸
BroMenn Regional Medical Center, Normal, Illinois, United States
🇺🇸
Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
🇺🇸
St. Joseph Medical Center, Bloomington, Illinois, United States

and more 116 locations

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2004-12-08

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00098462

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-11-10

Last Posted Date: 2016-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 74

Registration Number: NCT00096486

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2004-11-09

Last Posted Date: 2017-05-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 27

Registration Number: NCT00095836

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Phase 1

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2015-10-06

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00093652

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy